<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480737</url>
  </required_header>
  <id_info>
    <org_study_id>BradleyH</org_study_id>
    <nct_id>NCT03480737</nct_id>
  </id_info>
  <brief_title>rTMS and EF Training for Working Memory Deficits in Adolescent Psychopathology</brief_title>
  <official_title>rTMS and Executive Functioning Training for Working Memory Deficits in Adolescent Psychopathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bradley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bradley Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Executive functioning (EF) deficits are a core, transdiagnostic feature of psychopathology&#xD;
      and one of the strongest predictors of clinical and functional outcomes, yet there remains a&#xD;
      dearth of treatments available for EF deficits. EF is a collection of cognitive control&#xD;
      processes that includes working memory (i.e., maintain/manipulate data not perceptually&#xD;
      present), inhibition (i.e., inhibit/control of attention, thoughts, behaviors) and&#xD;
      flexibility (i.e., shift flexibly between tasks/sets). These EF subdomains are subserved by a&#xD;
      network (i.e., cognitive control network) of frontal (e.g., dorsolateral prefrontal cortex&#xD;
      [DLPFC]), parietal and subcortical regions, with hypoactivation in such regions often&#xD;
      underlying EF deficits. There is a recent call in psychiatry to develop experimental&#xD;
      therapeutics that target anomalous neural systems underlying symptomology. Repetitive&#xD;
      transcranial magnetic stimulation (rTMS) is a therapeutic, non-invasive method of cortical&#xD;
      excitability modulation. High frequency rTMS to the left DPLFC has an activating effect on&#xD;
      the cognitive control network, with initial research in adults finding a subsequent enhancing&#xD;
      effect on working memory, inhibition, and flexibility. rTMS represents a very promising&#xD;
      potential tool to target EF deficits in psychopathology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared to sham condition, activation of the left DLPFC prior to EF training will temporarily increase working memory performance as measured by the Sternberg Spatial Working Memory Test</measure>
    <time_frame>Task performance will be measured immediately prior to and following the active and sham rTMS/EF training sessions.</time_frame>
    <description>The SWMT is a performance-based neuropsychological test of working memory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compared to sham condition, activation of the left DLPFC prior to EF training will temporarily increase fronto-parietal gamma power and theta-gamma coupling during working memory demands.</measure>
    <time_frame>EEG will be measured during SWMT immediately prior to and following the active and sham rTMS/EF training sessions.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>ADHD With Working Memory Deficits</condition>
  <arm_group>
    <arm_group_label>10 Hz rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham rTMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>iTBS rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim Super Rapid2 stimulator, 10 Hz condition</intervention_name>
    <description>10 Hz (2,000 pulses) at left DLPFC</description>
    <arm_group_label>10 Hz rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim Super Rapid2 stimulator, Sham condition</intervention_name>
    <description>sham</description>
    <arm_group_label>Sham rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magstim Super Rapid2 stimulator, iTBS condition</intervention_name>
    <description>50 Hz, iTBS (600 pulses) at left DLPFC</description>
    <arm_group_label>iTBS rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide assent and have parent provide parental permission&#xD;
&#xD;
          2. English fluency&#xD;
&#xD;
          3. 13-17 years&#xD;
&#xD;
          4. List Sorting Test (NIH Toolbox) performance: Greater than 1.0 standard deviation (SD)&#xD;
             below normative mean&#xD;
&#xD;
          5. Parent rating on BRIEF-2 Working Memory: Greater than 1.0 SD above normative mean&#xD;
&#xD;
          6. IQ &gt; 80&#xD;
&#xD;
          7. Clinical diagnosis of attention deficit hyperactivity disorder (ADHD): predominantly&#xD;
             inattentive type, predominantly hyperactive/impulsive type, combined type, or&#xD;
             unspecified type. Diagnostic criteria will be confirmed with NICHQ Vanderbilt&#xD;
             Assessment Scales-Parent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be screened to exclude individuals with neurological or medical&#xD;
        conditions that might confound the results, as well as to exclude participants in whom rTMS&#xD;
        might result in increased risk of side effects or complications. Common TMS&#xD;
        contraindications include metallic hardware in the body, cardiac pacemaker, patients with&#xD;
        an implanted medication pumps or an intracardiac line, or prescription of medications known&#xD;
        to lower seizure threshold. This accounts for the majority of the exclusion criteria&#xD;
        listed:&#xD;
&#xD;
          1. Intracranial pathology from a known genetic disorder (e.g., NF1, tuberous sclerosis)&#xD;
             or from acquired neurologic disease (e.g. stroke, tumor), cerebral palsy, history of&#xD;
             severe head injury, or significant dysmorphology&#xD;
&#xD;
          2. History of fainting spells of unknown or undetermined etiology that might constitute&#xD;
             seizures&#xD;
&#xD;
          3. History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family&#xD;
             history epilepsy&#xD;
&#xD;
          4. Any progressive (e.g., neurodegenerative) neurological disorder&#xD;
&#xD;
          5. Chronic (particularly) uncontrolled medical conditions that may cause a medical&#xD;
             emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia,&#xD;
             asthma, etc.)&#xD;
&#xD;
          6. Contraindicated metal implants in the head, brain or spinal cord (excluding dental&#xD;
             implants or fillings)&#xD;
&#xD;
          7. Pacemaker&#xD;
&#xD;
          8. Implanted medication pump&#xD;
&#xD;
          9. Vagal nerve stimulator&#xD;
&#xD;
         10. Deep brain stimulator&#xD;
&#xD;
         11. TENS unit (unless removed completely for the study)&#xD;
&#xD;
         12. Ventriculo-peritoneal shunt&#xD;
&#xD;
         13. Signs of increased intracranial pressure&#xD;
&#xD;
         14. Intracranial lesion (including incidental finding on MRI)&#xD;
&#xD;
         15. History of head injury resulting in prolonged loss of consciousness&#xD;
&#xD;
         16. Substance abuse or dependence within past six months (i.e., DSM-5 substance use&#xD;
             disorder criteria met)&#xD;
&#xD;
         17. Chronic treatment with prescription medications that decrease cortical seizure&#xD;
             threshold&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Kavanaugh, PsyD</last_name>
    <role>Principal Investigator</role>
    <affiliation>E. P. Bradley Hospital/Alpert Medical School of Brown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Kavanaugh, PsyD</last_name>
    <phone>401 432 1359</phone>
    <email>brian_Kavanaugh@brown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anthony Spirito, PhD</last_name>
    <email>Anthony_Spirito@Brown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>E. P. Bradley Hospital</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Kavanaugh, PsyD</last_name>
      <phone>401-432-1359</phone>
      <email>Brian_Kavanaugh@Brown.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

